These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

693 related items for PubMed ID: 14750581

  • 1. Unexplained delayed nerve impairment in leprosy after treatment.
    Rosenberg NR, Faber WR, Vermeulen M.
    Lepr Rev; 2003 Dec; 74(4):357-65. PubMed ID: 14750581
    [Abstract] [Full Text] [Related]

  • 2. Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia.
    Becx-Bleumink M, Berhe D.
    Int J Lepr Other Mycobact Dis; 1992 Jun; 60(2):173-84. PubMed ID: 1522359
    [Abstract] [Full Text] [Related]

  • 3. The prognostic importance of detecting mild sensory impairment in leprosy: a randomized controlled trial (TRIPOD 2).
    Van Brakel WH, Anderson AM, Withington SG, Croft RP, Nicholls PG, Richardus JH, Smith WC.
    Lepr Rev; 2003 Dec; 74(4):300-10. PubMed ID: 14750575
    [Abstract] [Full Text] [Related]

  • 4. The INFIR Cohort Study: investigating prediction, detection and pathogenesis of neuropathy and reactions in leprosy. Methods and baseline results of a cohort of multibacillary leprosy patients in north India.
    van Brakel WH, Nicholls PG, Das L, Barkataki P, Suneetha SK, Jadhav RS, Maddali P, Lockwood DN, Wilder-Smith E, Desikan KV.
    Lepr Rev; 2005 Mar; 76(1):14-34. PubMed ID: 15881033
    [Abstract] [Full Text] [Related]

  • 5. Impairments and Hansen's disease control in Rondônia state, Amazon region of Brazil.
    De Oliveira CR, De Alencar Mde J, De Sena Neto SA, Lehman LF, Schreuder PA.
    Lepr Rev; 2003 Dec; 74(4):337-48. PubMed ID: 14750579
    [Abstract] [Full Text] [Related]

  • 6. Erythema nodosum leprosum in Nepal: a retrospective study of clinical features and response to treatment with prednisolone or thalidomide.
    Feuth M, Brandsma JW, Faber WR, Bhattarai B, Feuth T, Anderson AM.
    Lepr Rev; 2008 Sep; 79(3):254-69. PubMed ID: 19009975
    [Abstract] [Full Text] [Related]

  • 7. Treatment with corticosteroids of long-standing nerve function impairment in leprosy: a randomized controlled trial (TRIPOD 3).
    Richardus JH, Withington SG, Anderson AM, Croft RP, Nicholls PG, Van Brakel WH, Smith WC.
    Lepr Rev; 2003 Dec; 74(4):311-8. PubMed ID: 14750576
    [Abstract] [Full Text] [Related]

  • 8. Delay in presentation, an indicator for nerve function status at registration and for treatment outcome--the experience of the Bangladesh Acute Nerve Damage Study cohort.
    Nicholls PG, Croft RP, Richardus JH, Withington SG, Smith WC.
    Lepr Rev; 2003 Dec; 74(4):349-56. PubMed ID: 14750580
    [Abstract] [Full Text] [Related]

  • 9. A clinical prediction rule for nerve function impairment in leprosy patients-revisited after 5 years of follow-up.
    Croft RP, Nicholls PG, Steyerberg EW, Richardus JH, Withington SG, Smith WC.
    Lepr Rev; 2003 Mar; 74(1):35-41. PubMed ID: 12669931
    [Abstract] [Full Text] [Related]

  • 10. Adverse events of standardized regimens of corticosteroids for prophylaxis and treatment of nerve function impairment in leprosy: results from the 'TRIPOD' trials.
    Richardus JH, Withington SG, Anderson AM, Croft RP, Nicholls PG, Van Brakel WH, Smith WC.
    Lepr Rev; 2003 Dec; 74(4):319-27. PubMed ID: 14750577
    [Abstract] [Full Text] [Related]

  • 11. Recognizing and managing the immunologic reactions in leprosy.
    Kamath S, Vaccaro SA, Rea TH, Ochoa MT.
    J Am Acad Dermatol; 2014 Oct; 71(4):795-803. PubMed ID: 24767732
    [Abstract] [Full Text] [Related]

  • 12. [Pentoxifylline in the treatment of erythema nodosum leprosum: results of an open study].
    de Carsalade GY, Achirafi A, Flageul B.
    Acta Leprol; 2003 Oct; 12(3):117-22. PubMed ID: 15040702
    [Abstract] [Full Text] [Related]

  • 13. Bangkok Workshop on Leprosy Research. Treatment of reactions and nerve damage.
    Naafs B.
    Int J Lepr Other Mycobact Dis; 1996 Dec; 64(4 Suppl):S21-8. PubMed ID: 9030120
    [No Abstract] [Full Text] [Related]

  • 14. Some unusual type 2 reactions in leprosy.
    Ramesh V, Pahwa M.
    Int J Dermatol; 2010 Feb; 49(2):172-5. PubMed ID: 20465641
    [Abstract] [Full Text] [Related]

  • 15. The effect of corticosteroid usage on the bacterial killing, clearance and nerve damage in leprosy: a prospective cohort study: part 1--study design and baseline findings of 400 untreated multibacillary patients.
    Khambati FA, Shetty VP, Ghate SD, Capadia GD, Pai VV, Ganapati R.
    Lepr Rev; 2008 Jun; 79(2):134-53. PubMed ID: 18711936
    [Abstract] [Full Text] [Related]

  • 16. Epidemiological characteristics of leprosy reactions: 15 years experience from north India.
    Kumar B, Dogra S, Kaur I.
    Int J Lepr Other Mycobact Dis; 2004 Jun; 72(2):125-33. PubMed ID: 15301592
    [Abstract] [Full Text] [Related]

  • 17. The occurrence of reactions and impairments in leprosy: experience in the leprosy control program of three provinces in northeastern Thailand, 1987-1995 [correction of 1978-1995]. III. Neural and other impairments.
    Schreuder PA.
    Int J Lepr Other Mycobact Dis; 1998 Jun; 66(2):170-81. PubMed ID: 9728449
    [Abstract] [Full Text] [Related]

  • 18. Risk factors for erythema nodosum leprosum.
    Manandhar R, LeMaster JW, Roche PW.
    Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):270-8. PubMed ID: 10575406
    [Abstract] [Full Text] [Related]

  • 19. Reaction cases treated at the Regional Leprosy Training and Research Institute, Aska, Orissa: a retrospective analysis.
    Santaram V, Porichha D.
    Indian J Lepr; 2004 Sep; 76(4):310-20. PubMed ID: 16119141
    [Abstract] [Full Text] [Related]

  • 20. Epidemiologic characteristics of leprosy reactions.
    Scollard DM, Smith T, Bhoopat L, Theetranont C, Rangdaeng S, Morens DM.
    Int J Lepr Other Mycobact Dis; 1994 Dec; 62(4):559-67. PubMed ID: 7868954
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.